ISRCTN03626626已完成不适用
Phase IIa trial of interferon-beta-1a (Avonex) in patients with rheumatoid arthritis
Biogen Idec Inc. (USA)0 个研究点目标入组 22 人开始时间: 2003年10月23日最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- 入组人数
- 22
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •1. Greater than 18 years old who meet the American College of Rheumatology criteria for Rheumatoid Arthritis (RA)
- •2. Failed at least one currently available Disease Modifying Anti-Rheumatic Drug (DMARD)
- •3. Active RA with greater than 6 swollen and 6 tender joints
- •4. C-Reactive Protein (CRP) exceeding 1.0 mg/dl
排除标准
- •Not provided at time of registration
研究者
相似试验
已完成
2 期
Interferon-beta1a (AVONEX) Treatment of Ulcerative ColitisUlcerative ColitisNCT00048347National Institute of Allergy and Infectious Diseases (NIAID)18
进行中（未招募）
不适用
A phase II study about interferon gamma 1b to therapy the steroid-refractory bronchiolitis obliterans after allogenic stem cell therapysteroid-refractory bronchiolitis obliteransMedDRA version: 13.1Level: PTClassification code 10029888Term: Obliterative bronchiolitisSystem Organ Class: 10038738 - Respiratory, thoracic and mediastinal disordersEUCTR2010-022467-36-DEFreistaat Bayern
招募中
3 期
Efficacy and safety of Interferon beta-1-a in mild to moderate COVID-19IRCT20120703010178N25Shahid Beheshti University of Medical Sciences100
尚未招募
1 期
INFINiTE-CV2 Phase I Trial: INterFeron type 1 Intra-Nasal gel Therapy for Early treatment of SARS-CoV2 (COVID-19)COVID-19Respiratory - Other respiratory disorders / diseasesInfection - Other infectious diseasesACTRN12622000094774Dr Edmund Lau20
招募中
3 期
ReciGen for treatment of Covid-19Covid 19.COVID-19, virus identifiedU07.1IRCT20150914024017N1Tehran University of Medical Sciences40